Cargando…

Fatty liver formation in fulminant type 1 diabetes

A 32-year-old woman presented with 3days of epigastric pain and was admitted to our hospital (day 3 of disease). We diagnosed acute pancreatitis based on epigastric abdominal pain, hyperamylasemia, and an inflammatory reaction of withdrawn blood, pancreatic enlargement, and so on. Her condition impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Takashi, Ushiroda, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356111/
https://www.ncbi.nlm.nih.gov/pubmed/30367750
http://dx.doi.org/10.1530/EDM-15-0121
_version_ 1783391460041687040
author Matsuo, Takashi
Ushiroda, Yoshihiko
author_facet Matsuo, Takashi
Ushiroda, Yoshihiko
author_sort Matsuo, Takashi
collection PubMed
description A 32-year-old woman presented with 3days of epigastric pain and was admitted to our hospital (day 3 of disease). We diagnosed acute pancreatitis based on epigastric abdominal pain, hyperamylasemia, and an inflammatory reaction of withdrawn blood, pancreatic enlargement, and so on. Her condition improved with treatment; however, on day 8, she had decreased level of consciousness. Laboratory results led to a diagnosis of fulminant type 1 diabetes mellitus (FT1DM) with concomitant diabetic ketoacidosis. Insulin therapy improved her blood glucose levels as well as her symptoms. Fatty liver with liver dysfunction was observed on day 14, which improved by day 24. Blood levels of free fatty acids (FFAs) increased rapidly from 440μEq/L (normal range: 140–850μEq/L) on day 4 to 2097μEq/L on days 7–8 (onset of FT1DM) and subsequently decreased to 246μEq/L at the onset of fatty liver. The rapid decrease in insulin at the onset of FT1DM likely freed fatty acids derived from triglycerides in peripheral adipocytes into the bloodstream. Insulin therapy rapidly transferred FFAs from the periphery to the liver. In addition, insulin promotes the de novo synthesis of triglycerides in the liver, using newly acquired FFAs as substrates. At the same time, inhibitory effects of insulin on VLDL secretion outside of the liver promote the accumulation of triglycerides in the liver, leading to fatty liver. We describe the process by which liver dysfunction and severe fatty liver occurs after the onset of FT1DM, from the perspective of disturbed fatty acid metabolism. LEARNING POINTS: FT1DM is rare but should be considered in patients with pancreatitis and a decreased level of consciousness. Fatty liver should be considered in patients with FT1DM when liver dysfunction is observed. Insulin is involved in mechanisms that promote fatty liver formation. Pathophysiological changes in fatty acid metabolism may provide clues on lipid metabolism in the early phases of FT1DM.
format Online
Article
Text
id pubmed-6356111
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-63561112019-02-05 Fatty liver formation in fulminant type 1 diabetes Matsuo, Takashi Ushiroda, Yoshihiko Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy A 32-year-old woman presented with 3days of epigastric pain and was admitted to our hospital (day 3 of disease). We diagnosed acute pancreatitis based on epigastric abdominal pain, hyperamylasemia, and an inflammatory reaction of withdrawn blood, pancreatic enlargement, and so on. Her condition improved with treatment; however, on day 8, she had decreased level of consciousness. Laboratory results led to a diagnosis of fulminant type 1 diabetes mellitus (FT1DM) with concomitant diabetic ketoacidosis. Insulin therapy improved her blood glucose levels as well as her symptoms. Fatty liver with liver dysfunction was observed on day 14, which improved by day 24. Blood levels of free fatty acids (FFAs) increased rapidly from 440μEq/L (normal range: 140–850μEq/L) on day 4 to 2097μEq/L on days 7–8 (onset of FT1DM) and subsequently decreased to 246μEq/L at the onset of fatty liver. The rapid decrease in insulin at the onset of FT1DM likely freed fatty acids derived from triglycerides in peripheral adipocytes into the bloodstream. Insulin therapy rapidly transferred FFAs from the periphery to the liver. In addition, insulin promotes the de novo synthesis of triglycerides in the liver, using newly acquired FFAs as substrates. At the same time, inhibitory effects of insulin on VLDL secretion outside of the liver promote the accumulation of triglycerides in the liver, leading to fatty liver. We describe the process by which liver dysfunction and severe fatty liver occurs after the onset of FT1DM, from the perspective of disturbed fatty acid metabolism. LEARNING POINTS: FT1DM is rare but should be considered in patients with pancreatitis and a decreased level of consciousness. Fatty liver should be considered in patients with FT1DM when liver dysfunction is observed. Insulin is involved in mechanisms that promote fatty liver formation. Pathophysiological changes in fatty acid metabolism may provide clues on lipid metabolism in the early phases of FT1DM. Bioscientifica Ltd 2016-07-28 /pmc/articles/PMC6356111/ /pubmed/30367750 http://dx.doi.org/10.1530/EDM-15-0121 Text en © 2016 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Insight into Disease Pathogenesis or Mechanism of Therapy
Matsuo, Takashi
Ushiroda, Yoshihiko
Fatty liver formation in fulminant type 1 diabetes
title Fatty liver formation in fulminant type 1 diabetes
title_full Fatty liver formation in fulminant type 1 diabetes
title_fullStr Fatty liver formation in fulminant type 1 diabetes
title_full_unstemmed Fatty liver formation in fulminant type 1 diabetes
title_short Fatty liver formation in fulminant type 1 diabetes
title_sort fatty liver formation in fulminant type 1 diabetes
topic Insight into Disease Pathogenesis or Mechanism of Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356111/
https://www.ncbi.nlm.nih.gov/pubmed/30367750
http://dx.doi.org/10.1530/EDM-15-0121
work_keys_str_mv AT matsuotakashi fattyliverformationinfulminanttype1diabetes
AT ushirodayoshihiko fattyliverformationinfulminanttype1diabetes